Tuesday, April 2, 2019 (HealthDay News)-Brain scans can improve diagnosis and management Alzheimer’s disease, A new study claims.
This scanning technique changed the diagnosis of the cause of mental illness in more than one-third of the study participants.
According to a study published on April 2, brain scan results in nearly two-thirds of cases also changed management (including medication and counseling use). Journal of American Medical Association..
“These results provide very reliable and extensive evidence that amyloid PET imaging can be a powerful tool for improving accuracy. Alzheimer’s disease It leads to better medical management, especially when it is difficult to make a diagnosis. ” Alzheimer’s disease Association.
“It’s important that amyloid PET imaging is more accessible to those who need it,” she added in a news release from the association.
This study was funded by Avid Radiopharmaceuticals Inc., General Electric Healthcare, and Life Molecular Imaging.
“I was impressed with the magnitude of these results, which revealed that amyloid PET imaging could have a significant impact on the way patients are diagnosed and cared for. Alzheimer’s disease And other forms of cognitive decline. “Lead author Dr. Gil Rabinovic said with memory aging Center at the University of California, San Francisco.
Early diagnosis also means that patients and their families can plan for the future, including safety, care, legal and financial issues, and have access to resources and support programs.
In this study, PET scans accounted for about one-third of previously diagnosed patients. Alzheimer’s disease There was no significant amyloid accumulation, overturning the diagnosis of Alzheimer’s disease.
However, in nearly half of patients previously undiagnosed with Alzheimer’s disease, PET scans revealed significant accumulation of amyloid plaques, leading to a new diagnosis of Alzheimer’s disease.
One-third of study participants previously referred to for Alzheimer’s disease Clinical trial No signs of amyloid accumulation were shown based on PET scans. Based on these results, physicians were able to confirm that nearly all (93%) of patients who mentioned the Alzheimer’s disease trial were amyloid-positive. This is essential to the success of these exams.
“An accurate diagnosis is essential to ensure that patients are receiving the most appropriate treatment. In particular, drugs for Alzheimer’s disease can exacerbate cognitive decline in people with other brain disorders. There is, “says Rabinovic.
“But perhaps more fundamentally, people who come to the clinic for memory problems are looking for answers. With an early definitive diagnosis, individuals participate in planning for the next stage of life, otherwise. You can finally make the decisions you need. They are made by others. “
Copyright © 2019 Health Day. all rights reserved.
Source: Alzheimer’s Disease Association, News Release, April 2, 2019
Brain scan spot, tracking of Alzheimer’s disease
Source link Brain scan spot, tracking of Alzheimer’s disease